周二（10月14日）盘中，港股晶泰控股（02228）股价出现显著上涨，涨幅高达8%，引发市场关注。该股的强劲表现远超生物科技行业0.97%的平均涨幅，凸显出投资者对公司前景的积极预期。
晶泰控股是一家专注于为制药及材料科学等产业提供研发解决方案的公司。其核心业务包括药物发现解决方案和智能自动化解决方案，服务对象涵盖国内外的生物技术与制药公司以及学术机构。公司最新财报显示，营业收入达5.67亿港元，净利润为9,078.90万港元，每股收益0.0252港元，显示出稳健的财务状况。
值得注意的是，尽管前一交易日（10月13日）南向资金减持了该股1384.90万股，但这似乎并未影响投资者的信心。相反，机构投资者对晶泰控股保持高度看好，在参与评级的5家券商中，100%给予"买入"建议。这种一致的积极评价可能是推动股价上涨的重要因素之一。此外，生物科技行业整体向好，也为晶泰控股的股价上涨提供了有利的市场环境。投资者应密切关注公司后续发展及行业动态，理性看待股价波动。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.